ClinicalTrials.gg
RecruitingNCT06568367Updated Jul 24, 2026

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

A Phase 3 interventional study of Solriamfetol 150 mg and Solriamfetol 300 mg in Excessive Sleepiness and Shift-work Disorder, sponsored by Axsome Therapeutics, Inc.. Recruiting at 49 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing solriamfetol in Disorders of Excessive Somnolence — 3 open to participants now, 3 under way, 2 of them phase 3. solriamfetol · Disorders of Excessive Somnolence.

Planned enrollment
2nd of 12
520 · median 75
Started
2024
with 3 others
Phase 3
3 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
4 of 12
Axsome Therapeutics, Inc.

Among the 12 studies testing solriamfetol in Disorders of Excessive Somnolence, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2024, is one of 3 in phase 3, and was the 11th registered.

Disorders of Excessive Somnolence

196 studies on the registry are indexed under Disorders of Excessive Somnolence; 34 are open to participants now.

Browse Disorders of Excessive Somnolence studies →

Open to participants now

3 of the 12 studies testing solriamfetol in Disorders of Excessive Somnolence are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About solriamfetol

solriamfetol: first FDA approval 2019 (SUNOSI), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Disorders of Excessive Somnolence studies recruiting now, 12 (40%) set no upper age limit and 17 (57%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing solriamfetol in Disorders of Excessive Somnolence, or all of them as a file.
02

Study summary

SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).

Read the detailed description

Eligible subjects must meet the International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria for Shift Work Disorder (SWD). Subjects will be randomized in a 1:1:1 ratio to receive solriamfetol titrated to either 150 mg, 300 mg, or placebo once per night shift for 12 weeks.

03

Conditions studied

  • Excessive Sleepiness
  • Shift-work Disorder

Keywords

  • Excessive Sleepiness
  • Solriamfetol
  • Sunosi
  • SWD
  • Dopamine norepinephrine reuptake inhibitor
  • Non-stimulant therapy
  • Insomnia
  • Circadian Rhythm Sleep Disorder
  • Trace amine-associated receptor 1 (TAAR1) agonist
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria for Shift Work Disorder (SWD)
  • Provides written to participate in the study before the conduct of any study procedures.
  • Male or female, aged 18 to 65 inclusive.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription.
  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
520 participants (estimated)

Study arms

  • Experimental
    Solriamfetol 150mg

    Up to 12 weeks

    Drug: Solriamfetol 150 mg

  • Experimental
    Solriamfetol 300mg

    Up to 12 weeks

    Drug: Solriamfetol 300 mg

  • Placebo comparator
    Placebo

    Up to 12 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 12 in the mean sleep latency time as measured by the Maintenance of Wakefulness Test (MWT).

    Time frame: 12 weeks

  2. Change from Baseline to Week 12 in the Clinical Global Impressions of Severity of Illness (CGI-S) for sleepiness during the night shift.

    Time frame: 12 weeks

07

Study locations

46 of 49 sites recruiting
  • Clinical Research Site
    Auburn, Alabama 36832, United States
    Recruiting
  • Clinical Research Site
    Cullman, Alabama 35055, United States
    Recruiting
  • Clinical Research Site
    Chandler, Arizona 85224, United States
    Recruiting
  • Clinical Research Site
    Tucson, Arizona 85704, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clinical Research Site
    Little Rock, Arkansas 72211, United States
    Recruiting
  • Clinical Research Site
    Anaheim, California 92801, United States
    Recruiting
  • Clinical Research Site
    Cerritos, California 90703, United States
    Recruiting
  • Clinical Research Site
    Chula Vista, California 91910, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Clinical Research Site
    Huntington Beach, California 92647, United States
    Recruiting
  • Clinical Research Site
    Long Beach, California 90805, United States
    Recruiting
  • Clinical Research Site
    Santa Ana, California 92705, United States
    Recruiting
  • Clinical Research Site
    Colorado Springs, Colorado 80918, United States
    Recruiting
  • Clinical Research Site
    Brandon, Florida 33511, United States
    Recruiting
  • Clinical Research Site
    Hialeah, Florida 33016, United States
    Recruiting
  • Clinical Research Site
    Miami, Florida 33135, United States
    Recruiting
  • Clinical Research Site
    Miami, Florida 33144, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clinical Research Site
    Miami, Florida 33176, United States
    Recruiting
  • Clinical Research Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Clinical Research Site
    Atlanta, Georgia 30238, United States
    Recruiting
  • Clinical Research Site
    Stockbridge, Georgia 30281, United States
    Recruiting
  • Clinical Research Site
    Chicago, Illinois 60634, United States
    Recruiting
  • Clinical Research Site
    Kenner, Louisiana 70065, United States
    Recruiting
  • Clinical Research Site
    Towson, Maryland 21286, United States
    Recruiting
  • Clinical Research Site
    Boston, Massachusetts 02115, United States
    Recruiting
  • Clinical Research Site
    Lansing, Michigan 48911, United States
    Recruiting
  • Clinical Research Site
    Novi, Michigan 48377, United States
    Recruiting
  • Clinical Research Site
    Southfield, Michigan 48075, United States
    Recruiting
  • Clinical Research Site
    Chesterfield, Missouri 63017, United States
    Recruiting
  • Clinical Research Site
    St Louis, Missouri 63123, United States
    Recruiting
  • Clinical Research Site
    Henderson, Nevada 89052, United States
    Recruiting
  • Clinical Research Site
    Middletown, New Jersey 07748, United States
    Recruiting
  • Clinical Research Site
    Denver, North Carolina 28037, United States
    Recruiting
  • Clinical Research Site
    Fayetteville, North Carolina 28304, United States
    Recruiting
  • Clinical Research Site
    Huntersville, North Carolina 28078, United States
    Recruiting
  • Clinical Research Site
    Cincinnati, Ohio 45212, United States
    Recruiting
  • Clinical Research Site
    Cincinnati, Ohio 45245, United States
    Recruiting
  • Clinical Research Site
    Wyomissing, Pennsylvania 19610, United States
    Recruiting
  • Clinical Research Site
    Charleston, South Carolina 29425, United States
    Recruiting
  • Clinical Research Site
    Columbia, South Carolina 29201, United States
    Recruiting
  • Clinical Research Site
    Houston, Texas 77058, United States
    Recruiting
  • Clinical Research Site
    Houston, Texas 77070, United States
    Recruiting
  • Clinical Research Site
    San Antonio, Texas 78229, United States
    Recruiting
  • Clinical Research Site
    Sugar Land, Texas 77478, United States
    Recruiting
  • Clinical Research Site
    Spokane, Washington 99204, United States
    Recruiting
  • Clinical Research Site
    Calgary, Alberta T2Z 3A6, Canada
    Recruiting
  • Clinical Research Site
    Markham, Ontario L3R 1A3, Canada
    Recruiting
  • Clinical Research Site
    Ottawa, Ontario K2C 0P7, Canada
    Recruiting
  • Clinical Research Site
    Toronto, Ontario M4N 4M5, Canada
    Recruiting
  • Clinical Research Site
    Toronto, Ontario M5S 3A3, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 23, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06568367
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Aug 1, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 24, 2026

Study contacts

Study Director
Contact
sol-swd-301@axsome.com
212-332-5061

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion